Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Apr;10(Suppl 7):S838-S845.
doi: 10.21037/jtd.2018.04.08.

The role of liquid biopsy in predicting post-operative recurrence of non-small cell lung cancer

Hengrui Liang  1   2   3 , Jianbin Huang  3 , Bo Wang  3 , Zhichao Liu  3 , Jianxing He  1   2 , Wenhua Liang  1   2
Affiliations

The role of liquid biopsy in predicting post-operative recurrence of non-small cell lung cancer

Hengrui Liang et al. J Thorac Dis. 2018 Apr.

Abstract

Background: Radical resection is the cornerstone for patients with early stage of non-small cell lung cancer (NSCLC). However, fatal disease recurs in about 30-70% of resected cases. The circulating tumor cells (CTCs) is one of the main causes of recurrence of cancer. Circulating tumor DNA (ctDNA) is also a potential predictive biomarker of recurrence in patients with early stage NSCLC. A meta-analysis was conducted to identify the prognostic value of the CTCs and ctDNA in predicting the disease recurrence after surgery of NSCLC patients.

Methods: Electronic databases were comprehensively searched for eligible studies. A random effects model was used. The primary endpoint was the hazards ratio (HR) for the disease-free survival (DFS) between CTCs/ctDNA positive and negative groups. The relative risks (RR) of one and two-year recurrence rate between CTCs/ctDNA positive and negative groups were also calculated.

Results: A total of 5 studies involving 351 patients were included, in which 3 were studies on CTCs and 2 were ctDNA. Our result revealed that positive peripheral blood CTCs (HR, 3.37; 95% CI: 2.28-4.96; P<0.001) and ctDNA (HR, 8.15; 95% CI: 2.11-31.50; P=0.002) indicated poor prognosis for DFS. One (68% vs. 18.2%; RR 3.28; P<0.001) and two (76% vs. 44%; RR 1.80; P=0.06) years recurrence rate were higher in CTCs positive group compared with the negative group, respectively. The same result was also observed in ctDNA positive versus negative groups of 1 (77.9% vs. 8.3%; RR 9.05; P=0.001) and 2 (85.6% vs. 8.3%; RR 9.63; P<0.001) years recurrence rate.

Conclusions: Both postoperative CTCs and ctDNA are promising predictive biomarkers of early tumor recurrence in NSCLC patients. In addition, detection based on ctDNA seems to be more sensitive than CTCs.

Keywords: Non-small cell lung cancer (NSCLC); circulating tumor DNA (ctDNA); circulating tumor cell (CTC); recurrence.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Flow diagram detailing the search strategy and identification of studies.
Figure 2
Figure 2
The correlation of CTCs/ctDNA with tumor recurrence in post-operative NSCLC patients. CTCs, circulating tumor cells; ctDNA, circulating tumor DNA; NSCLC, non-small cell lung cancer.
Figure 3
Figure 3
The correlation of CTCs/ctDNA with one-year recurrence rate. CTCs, circulating tumor cells; ctDNA, circulating tumor DNA.
Figure 4
Figure 4
The correlation of CTCs/ctDNA with two-year recurrence rate. CTCs, circulating tumor cells; ctDNA, circulating tumor DNA.
See this image and copyright information in PMC

References

    1. Ettinger DS, Wood DE, Aisner DL, et al. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2017;15:504-35. 10.6004/jnccn.2017.0050 - DOI - PubMed
    1. Früh M, Rolland E, Pignon JP, et al. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. J Clin Oncol 2008;26:3573-81. 10.1200/JCO.2008.16.2727 - DOI - PubMed
    1. Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 2017;545:446-51. 10.1038/nature22364 - DOI - PMC - PubMed
    1. Sawabata N, Okumura M, Utsumi T, et al. Circulating tumor cells in peripheral blood caused by surgical manipulation of non-small-cell lung cancer: pilot study using an immunocytology method. Gen Thorac Cardiovasc Surg 2007;55:189-92. 10.1007/s11748-007-0101-2 - DOI - PubMed
    1. Hofman V, Bonnetaud C, Ilie MI, et al. Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker. Clin Cancer Res 2011;17:827-35. 10.1158/1078-0432.CCR-10-0445 - DOI - PubMed

LinkOut - more resources